

Original Article

Prognostic significance of aromatase and estrogen receptor beta expression in *EGFR* wild-type lung adenocarcinoma

Kazumi Tanaka¹, Kimihiro Shimizu¹, Seiichi Kakegawa¹, Yoichi Ohtaki¹, Toshiteru Nagashima¹, Kyoichi Kaira², Jun Horiguchi¹, Tetsunari Oyama³, Izumi Takeyoshi¹

Departments of ¹Thoracic and Visceral Organ Surgery, ²Medicine and Molecular Science, ³Division of Diagnostic Pathology, Graduate School of Medicine, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan

Received August 25, 2015; Accepted December 15, 2015; Epub January 15, 2016; Published January 30, 2016

Abstract: Objectives: Based on recent findings of aromatase and estrogen receptor beta (ER β) expression in non-small-cell lung cancer, we assessed the clinicopathological and prognostic significance of aromatase and ER β expression and their relationship to epidermal growth factor receptor (*EGFR*) mutation in lung adenocarcinoma. Materials and methods: We evaluated 150 resected primary lung adenocarcinoma specimens. Expression of aromatase, ER α , ER β , progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was evaluated by immunostaining, and *EGFR* and *KRAS* mutations were analyzed. Overall survival (OS) and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method. Results: Expression of aromatase, ER α , ER β , PR, and HER2 was detected in 88.0%, 1.3%, 79.3%, 2.7%, and 39.3% of specimens, respectively. In patients with *EGFR* wild-type lung adenocarcinoma, high aromatase expression was an independent predictor of poor OS (hazard ratio [HR]=2.638; 95% confidence interval [CI], 1.173-5.936; $P=.019$) and RFS (HR=2.505; 95% CI, 1.154-5.434; $P=.020$). Positive ER β expression was also an independent predictor of poor RFS (HR=4.013; 95% CI, 1.219-13.207; $P=.022$). Furthermore, high aromatase expression was a significant predictor of poor survival only in females (OS, $P=.010$; RFS, $P=.007$), whereas positive ER β expression was an important predictor of poor survival only in males (OS, $P=.073$; RFS, $P=.051$). No prognostic significance was observed in patients with *EGFR* mutations. Conclusions: Our findings suggest that *EGFR* wild-type lung adenocarcinoma is an estrogen-dependent carcinoma, and aromatase expression and ER β expression are potent prognostic markers for *EGFR* wild-type lung adenocarcinoma.

Keywords: Aromatase, estrogen receptor beta (ER β), estrogen signaling pathway, *EGFR* mutation, lung adenocarcinoma

Introduction

Lung cancer is one of the most common cancers globally and is currently the leading cause of death in both females and males [1]. Smoking remains the major cause of lung cancer, but ~53% of all females with lung cancer are non-smokers [2]. Interestingly, a gradual increase in the adenocarcinoma subtype of lung cancer has been reported, despite a decline in the smoking population [3-4]. Therefore, etiologic factors other than tobacco may also play a role in the development of lung adenocarcinoma.

Epidermal growth factor receptor (*EGFR*) is the most frequently mutated proto-oncogene, par-

ticularly in lung adenocarcinoma of non-smoker females, and its mutations are thought to play an important role in carcinogenesis [5]. However, recent evidence has suggested that estrogen may also play an important role in the development of non-small cell lung cancer (NSCLC), particularly adenocarcinoma [6]. Several studies have reported that estrogen stimulates the proliferation and progression of lung carcinoma cells, functions that were shown to be significantly suppressed by antiestrogenic agents both in vitro and in vivo [7-10].

Estrogen is converted from androgen by aromatase, a key enzyme in estrogen biosynthesis. In addition to its expression in the ovary and pla-

Prognostic significance of aromatase/ER β in lung adenocarcinoma

Table 1. Clinicopathological factors of the patients

Characteristics	N	%
No. of patients	150	100.0
Age (year)		
Mean	66	
Range	36-84	
Sex		
Male	63	42.0
Female	87	58.0
Menopause		
Premenopausal	4	4.6
Postmenopausal	81	93.1
Unknown	2	2.3
Smoking status		
Ever-smoker	68	45.3
Non-smoker	82	54.7
Tumor diameter (mm)		
Mean	24	
Range	6-70	
Pathologic stage		
IA	85	56.7
IB	26	17.3
IIA	5	3.3
IIB	6	4.0
IIIA	22	14.7
IIIB	6	4.0
IV	0	0.0
Pleural invasion		
Absent	102	68.0
Present	48	32.0
Lymphatic invasion		
Absent	101	67.3
Present	49	32.7
Vascular invasion		
Absent	104	69.3
Present	46	30.7

centa, aromatase is present in male and female extragonadal tissues, including breast and lung [11]. Aromatase expression is elevated in certain malignancies, such as breast carcinomas, suggesting that tumor progression caused by stimulation of estrogen signaling pathway could be enhanced by circulating estrogen as well as by localized autocrine or paracrine production of estrogen by aromatase. Recently, aromatase expression in NSCLC has also been reported [12-14]. Weinberg et al. demonstrated

that aromatase was expressed in NSCLC cell lines, and aromatase inhibitor (AI) suppressed tumor growth in vitro and in vivo [12]. Mah et al. reported that low aromatase expression was associated with favorable survival in female NSCLC patients, particularly those older than 65 years [13].

In estrogen signaling pathway, estrogens exert their effects mainly via estrogen receptor (ER) [6]. ER is a hormone receptor, as is progesterone receptor (PR). ER has two isoforms, ER α and ER β , which are encoded by distinct genes and are expressed in various tissues or at various levels in the same tissue [15]. In the normal lung, ER β has been reported to be expressed at a higher level than ER α [9]. Although the expression patterns of ER α and ER β in NSCLC were highly inconsistent among these reports [6], most of the results showed that there were no or a low (under 10%) rate of ER α -positive cases and a higher rate (over 50%) of ER β -positive cases [16]. Previously, ER α was considered a tumor promoter, whereas ER β was believed to inhibit tumorigenesis [17]. However, recent studies have demonstrated that ER β can function as a tumor promoter in the absence of ER α expression [18-22]. The association between ER β expression and the prognosis of lung cancer patients remains controversial [23-27]. Wu et al. reported that ER β expression was associated with favorable prognosis in NSCLC [23]. However, Stabile et al. reported that ER β expression was associated with a poor prognosis in lung cancer [26].

Recent reports have suggested an interaction between *EGFR* pathway and estrogen signaling pathway in the development of breast and lung cancer; additionally, estrogen signaling pathway is regulated by membrane receptor tyrosine kinases, including EGFR and human epidermal growth factor receptor 2 (HER2) [26, 28-32]. The *EGFR* pathway becomes activated when estrogen is depleted, and ER β expression is increased following treatment with *EGFR* tyrosin kinase inhibitors (EGFR-TKIs) in NSCLC cells [33-35]. Nose et al. reported that strong nuclear expression of ER β is correlated with *EGFR* mutations in lung adenocarcinoma [31]. However, the role of aromatase and ER β in estrogen signaling pathway and the association between the expression of these proteins and clinicopathological factors, including *EGFR*

Prognostic significance of aromatase/ER β in lung adenocarcinoma

Table 2. Primary antibodies used in the present study

Antigen	Clone	Dilution	Source
ER α	1D5	1:50	DakoCytomation, Glostrup, Denmark
ER β	14C8	1:200	GeneTex, CA, USA
PR	PGR636	1:800	DakoCytomation, Glostrup, Denmark
Aromatase	#677/H7	1:1000	Contributed by Dr. Evans DB, Novartis, Basel, Switzerland
Ki-67	MIB1	1:150	DakoCytomation, Glostrup, Denmark
HER2	4B5	1:1	Ventana, Tucson, AZ, USA

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

mutation, in lung adenocarcinoma, are not well understood.

The purpose of the present study was to examine the correlation between aromatase/ER β expression and clinicopathological prognostic factors, including *EGFR* mutations, and to evaluate the prognostic significance in lung adenocarcinoma.

Materials and methods

Patients and tissue specimens

One hundred and fifty lung adenocarcinoma specimens were obtained from patients who underwent complete surgical resection consecutively from 2004 to 2008 at Gunma University Hospital. The clinicopathological factors of the patients are shown in **Table 1**. The disease stage was determined according to the seventh edition of the TNM classification for lung and pleural tumors [36]. All of the procedures were approved by the Ethics Committee on Human Research of Gunma University Graduate School of Medicine, and written informed consent was obtained from all of the patients before surgery.

Immunohistochemistry

Serial tissue sections of 4- μ m thickness sliced from paraffin-embedded specimens were used for immunohistochemistry using the labeled streptavidin-biotin method. Immunostaining for ER α , ER β , PR, aromatase, Ki-67, and HER2 was performed with the antibodies listed in **Table 2**. The slides were deparaffinized with xylene and rehydrated with ethanol. For ER α , PR, and Ki-67 analysis, antigen retrieval was performed according to the manufacturer's instructions. For ER β , antigen retrieval was carried out by autoclaving the slides in citrate buffer (0.01 mol/L) at 121°C for 5 min. For HER2, immunohisto-

chemical staining was performed using BenchMark XT (Ventana, Tucson, AZ, USA), an automatic immunohistochemical staining system. Nuclear positive immunoreactivity for ER α , ER β , and PR was counted among 1000 cells per case and was recorded as "positive" for positive results of more than 10% [14]. Immunoreactive intensity of ER β was scored into four phases (0, negative; 1+, weak; 2+, moderate; and 3+, strong). For Ki-67, 1000 cells were counted per case, and the proliferative activity was assessed as the percentage of Ki-67-stained nuclei (Ki-67 labeling index; LI) in each sample. Cytoplasmic staining for aromatase in over 10% of the cancer lesion was recorded as "positive", and immunoreactive intensity was scored into four phases (0, negative; 1+, weak; 2+, moderate; and 3+, strong) [6, 13]. HER2 immunoreactivity was evaluated using the DAKO HercepTest scoring system (DakoCytomation), and over 2+ was considered "positive". Two observers (K.T. and T.O.) who were unaware of the clinical data independently reviewed all pathological slides.


Gene mutation analysis

We examined *EGFR* and *KRAS* mutations in the present study. Genomic DNA was extracted from a 3- to 5-mm cube of tumor tissue using a DNA Mini Kit (Qiagen, Hilden, Germany) and subsequently diluted to 20 ng/ μ L. *KRAS* and *EGFR* mutations were analyzed by sequencing as described previously [37, 38].

Statistical analysis

Statistical analyses were performed using IBM SPSS Statistics 21.0 (IBM Co., Armonk, NY, USA). Student's *t*-test and chi-squared test were used to compare percentages and mean values, respectively. Survival was calculated using the Kaplan-Meier method and confirmed using the log-rank test. Overall survival (OS) was

Prognostic significance of aromatase/ER β in lung adenocarcinoma



Prognostic significance of aromatase/ER β in lung adenocarcinoma

Figure 1. Representative immunohistochemical staining of ER α , ER β , PR, and aromatase in lung adenocarcinoma. A. Negative staining of ER α ; B. Positive staining of ER α ; C. Negative staining of ER β ; D. Positive staining of ER β ; E. Negative staining of PR; F. Positive staining of PR; G. Negative staining of aromatase; H. Positive staining of aromatase.




Figure 2. Representative immunohistochemical staining pattern of aromatase in lung adenocarcinoma. Specimens were assigned one of four scores (0, negative; 1+, weak; 2+, moderate; and 3+, strong) according to the intensity of immunoreactivity. A, 0; B, 1+; C, 2+; D, 3+.

determined as the time from tumor resection to death from any cause. Recurrence-free survival (RFS) was defined as the time between tumor resection and first disease recurrence or death. The median follow up for survivors was 65.5 months (average, 63.7 months; range, 1-117 months). Variables with *P* value less than .05 after univariate analysis were entered into multivariate analysis using the Cox proportional hazards model. *P* < .05 was deemed to indicate statistical significance. The midpoint and median intensity (1.5) was used to define low and high aromatase expression as previously described [13]. For univariate and multivariate analyses, each continuous variable (age and Ki-67 LI) was dichotomized at the median value.

Results

Immunohistochemical analysis

Among the 150 cases, ER α , ER β , PR, aromatase, and HER2 were detected in 2 (1.3%), 119 (79.3%), 4 (2.7%), 132 (88.0%), and 7 (4.7%) cases, respectively. **Figure 1** shows representative staining for ER α , ER β , PR, and aromatase. Regarding the immunoreactive intensity of aromatase, 18 (12.0%) cases were scored as 0, 60 (40.0%) cases were scored as 1+, 51 (34.0%) cases were scored as 2+, and 21 (14.0%) cases were scored as 3+ (**Figure 2**). Therefore, low expression group comprised 78 (52.0%) cases, and high expression group comprised 72 (48.0%) cases. ER β staining was

Prognostic significance of aromatase/ERβ in lung adenocarcinoma

Table 3. Univariate and multivariate analyses of prognostic factors in all patients

Variable	No. of patients (%)		Univariate analysis				Multivariate analysis						
			5-year OS (%)	P value	5-year RFS (%)	P value	OS			RFS			
							HR	95% CI	P value	HR	95% CI	P value	
All cases	150	(100.0)	73.6		63.8								
Age (years: median 69)													
<69	72	(48.0)	81.6		72.1		1.000	-	-	1.000	-	-	
≥69	78	(52.0)	66.0	0.001	56.1	0.011	3.178	1.527-6.616	0.002	1.861	1.035-3.348	0.038	
Sex													
Male	63	(42.0)	69.5		60.2								
Female	87	(58.0)	76.6	0.106	66.3	0.150							
Smoking status													
Non-smoker	82	(54.7)	81.5		71.9		1.000	-	-	1.000	-	-	
Ever-smoker	68	(45.3)	63.8	0.004	54.0	0.005	0.770	0.343-1.729	0.526	0.989	0.549-1.779	0.969	
Pathologic stage													
I, II	122	(81.3)	84.2		76.1		1.000	-	-	1.000	-	-	
III	28	(18.7)	28.6	<0.001	10.7	<0.001	2.024	1.358-3.016	0.001	1.697	1.223-2.353	0.002	
Pleural invasion													
Absent	102	(68.0)	85.0		75.2		1.000	-	-	1.000	-	-	
Present	48	(32.0)	50.0	<0.001	39.6	<0.001	0.985	0.481-2.019	0.968	1.201	0.676-2.132	0.533	
Lymphatic invasion													
Absent	101	(67.3)	88.9		82.0		1.000	-	-	1.000	-	-	
Present	49	(32.7)	41.9	<0.001	26.5	<0.001	1.609	0.664-3.900	0.292	2.418	1.101-5.309	0.028	
Vascular invasion													
Absent	104	(69.3)	86.4		79.6		1.000	-	-	1.000	-	-	
Present	46	(30.7)	44.6	<0.001	28.3	<0.001	1.727	0.735-4.059	0.210	1.362	0.661-2.808	0.402	
EGFR mutation													
Mutant	62	(44.3)	83.8		69.3		1.000	-	-				
Wild type	78	(55.7)	65.1	0.001	58.8	0.079	2.954	1.245-7.009	0.014				
KRAS mutation													
Mutant	23	(16.4)	52.2		47.8		1.205	0.548-2.651	0.643				
Wild type	117	(83.6)	77.6	0.035	66.6	0.126	1.000	-	-				
Aromatase													
Low expression	78	(52.0)	81.7		70.3		1.000	-	-				
High expression	72	(48.0)	65.1	0.039	56.9	0.101	2.235	1.142-4.374	0.013				

Prognostic significance of aromatase/ERβ in lung adenocarcinoma

ERα												
Negative	148	(98.7)	73.9		64.0							
Positive	2	(1.3)	50.0	0.405	50.0	0.568						
ERβ												
Negative	31	(20.7)	76.9		74.2							
Positive	119	(79.3)	72.7	0.447	61.0	0.145						
PR												
Negative	146	(97.3)	73.6		63.5							
Positive	4	(2.7)	75.0	0.724	75.0	0.573						
HER2												
Negative	143	(95.3)	74.5		64.9				1.000	-	-	
Positive	7	(4.7)	57.1	0.091	42.9	0.015			3.093	1.151-8.311	0.025	
Ki-67 LI (%: median 11.5)												
Low score	75	(50.0)	87.7		84.0		1.000	-	-	1.000	-	-
High score	75	(50.0)	59.3	<0.001	43.3	<0.001	2.591	1.115-6.021	0.027	2.620	1.299-5.284	0.007

OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; *EGFR*, epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LI, labeling index.

Prognostic significance of aromatase/ER β in lung adenocarcinoma

Table 4. Univariate and multivariate analyses of prognostic factors in patients with *EGFR* wild-type lung adenocarcinoma

Variable	No. of patients (%)		Univariate analysis				Multivariate analysis						
			5-year OS (%)	P value	5-year RFS (%)	P value	OS			RFS			
							HR	95% CI	P value	HR	95% CI	P value	
All cases	78	(100.0)	65.1		58.8								
Age (years: median 69)													
<69	33	(42.3)	78.0		75.5		1.000	-	-	1.000	-	-	
\geq 69	45	(57.7)	55.6	0.003	46.7	0.003	3.497	1.436-8.514	0.006	2.775	1.193-6.455	0.018	
Sex													
Male	40	(51.3)	59.6		54.8								
Female	38	(48.7)	70.7	0.105	63.2	0.180							
Smoking status													
Non-smoker	34	(43.6)	79.1		70.6		1.000	-	-	1.000	-	-	
Ever-smoker	44	(56.4)	54.1	0.009	54.8	0.021	0.788	0.248-2.505	0.687	0.453	0.147-1.395	0.168	
Pathologic stage													
I, II	62	(79.5)	77.2		71.0		1.000	-	-	1.000	-	-	
III	16	(20.5)	18.8	<0.001	12.5	<0.001	1.917	1.158-3.175	0.011	1.715	1.037-2.836	0.036	
Pleural invasion													
Absent	47	(60.3)	82.9		76.4		1.000	-	-	1.000	-	-	
Present	31	(39.7)	38.7	<0.001	32.3	0.001	1.034	0.424-2.524	0.941	1.247	0.527-2.955	0.615	
Lymphatic invasion													
Absent	47	(60.3)	86.9		80.7		1.000	-	-	1.000	-	-	
Present	31	(39.7)	32.3	<0.001	25.8	<0.001	1.454	0.521-4.056	0.474	3.275	1.079-9.941	0.036	
Vascular invasion													
Absent	49	(62.8)	85.6		79.5		1.000	-	-	1.000	-	-	
Present	29	(37.2)	30.7	<0.001	24.1	<0.001	2.893	1.076-7.775	0.035	1.645	0.572-4.734	0.356	
KRAS mutation													
Mutant	23	(29.5)	52.2		47.8								
Wild type	55	(70.5)	70.6	0.473	63.4	0.430							
Aromatase													
Low expression	43	(55.1)	78.9		72.1		1.000	-	-	1.000	-	-	
High expression	35	(44.9)	48.2	0.005	42.9	0.010	2.638	1.173-5.936	0.019	2.505	1.154-5.434	0.020	
ER α													
Negative	76	(97.4)	65.5		59.1								
Positive	2	(2.6)	50.0	0.663	50.0	0.687							

Prognostic significance of aromatase/ER β in lung adenocarcinoma

ER β												
Negative	19	(24.4)	78.9		78.9				1.000	-	-	
Positive	59	(75.6)	60.5	0.079	52.3	0.031			4.013	1.219-13.207	0.022	
PR												
Negative	75	(96.2)	65.0		58.5							
Positive	3	(3.8)	66.7	0.638	66.7	0.637						
HER2												
Negative	74	(94.9)	66.1		59.5							
Positive	4	(5.1)	50.0	0.060	50.0	0.133						
Ki-67 LI (%: median 11.5)												
Low score	36	(46.2)	83.0		80.6		1.000	-	-	1.000	-	-
High score	42	(53.8)	49.5	<0.001	40.1	<0.001	1.634	0.501-5.334	0.416	2.239	0.752-6.666	0.148

OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LI, labeling index.

Prognostic significance of aromatase/ERβ in lung adenocarcinoma




Figure 3. Kaplan-Meier survival curves of 78 patients with *EGFR* wild-type lung adenocarcinoma according to the immunoreactivity results for aromatase and ERβ. A. Overall survival (OS) stratified by high versus low expression of aromatase. B. Recurrence-free survival (RFS) stratified by high versus low expression of aromatase. C. OS stratified by positive versus negative expression of ERβ. D. RFS stratified by positive versus negative expression of ERβ. E. OS stratified by combined high expression of aromatase/positive expression of ERβ versus combined low expression of aromatase/negative expression of ERβ versus others. F. RFS stratified by combined high expression of aromatase/positive expression of ERβ versus combined low expression of aromatase/negative expression of ERβ versus others.

seen in both the cytoplasm and nucleus. Regarding the immunoreactive intensity of ERβ, 31 cases were scored as 0 (20.7%), 98 as 1+

(65.3%), 18 as 2+ (12.0%), and 3 as 3+ (2.0%). Additionally, among the tumors that stained positive for ERβ, almost all of the tumor tissue

Prognostic significance of aromatase/ER β in lung adenocarcinoma




Figure 4. Kaplan-Meier survival curves of male and female patients with *EGFR* wild-type lung adenocarcinoma according to the immunoreactivity results for aromatase and ER β . A. Recurrence-free survival (RFS) of males stratified by high versus low expression of aromatase. B. RFS of females stratified by high versus low expression of aromatase. C. RFS of males stratified by positive versus negative expression of ER β . D. RFS of females stratified by positive versus negative expression of ER β . E. RFS of males stratified by combined high expression of aromatase/positive expression of ER β versus combined low expression of aromatase/negative expression of ER β versus others. F. RFS of females stratified by combined high expression of aromatase/positive expression of ER β versus combined low expression of aromatase/negative expression of ER β versus others.

Prognostic significance of aromatase/ER β in lung adenocarcinoma

stained positive. Therefore, ER β immunoreactivity was not scored using scoring system such as the Allred score [39].

Association between aromatase/ER β expression and clinicopathological factors, including EGFR and KRAS mutation

In 10 of the 150 cases, DNA could not be extracted because the specimen was too small. Among the remaining 140 cases, EGFR and KRAS mutations were found in 62 (44.3%) and 23 (16.4%) cases, respectively. The occurrences of these mutations were mutually exclusive. Aromatase expression status was significantly associated with pleural invasion ($P=.037$), and ER β expression was not significantly associated with clinicopathological factors (Table S1).

Survival analysis

On univariate analysis, 10 variables were found to be significantly associated with poor OS. For RFS, eight variables were identified as statistically significant factors (Table 3). Multivariate analysis demonstrated that older age, advanced pathological stage, EGFR wild-type status, high aromatase expression, and high Ki-67 LI score were significant independent predictors of poor OS; additionally, older age, advanced pathological stage, lymphatic invasion, HER2 expression, and high Ki-67 LI score were significant independent predictors of poor RFS (Table 3).

Survival analysis according to EGFR/KRAS mutation status

To clarify the prognostic significance of aromatase/ER β expression according to EGFR/KRAS mutation status, we examined survival analysis stratified by EGFR/KRAS mutation status. No relationship was found between survival and KRAS mutation status (data not shown); however, a significant relationship was found between survival and EGFR mutation status. On univariate analysis of the EGFR wild-type population, eight variables were significantly associated with poor OS. Regarding RFS, nine variables were identified as statistically significant factors (Table 4). Multivariate analysis showed that older age, advanced pathological stage, vascular invasion, and high aromatase expression were significant independent predictors of poor OS. Concerning RFS, older age, advanced pathological stage, lymphatic invasion, hi-

gh aromatase expression, and ER β positive status were significant independent predictors (Table 4).

Figure 3 shows the survival curves of 78 patients with EGFR wild-type lung adenocarcinoma according to aromatase and ER β expression, respectively. Interestingly, differences in survival became clearer when patients were stratified by aromatase and ER β expression. Patients with high aromatase expression had poor prognosis in both OS (Figure 3A; $P=.005$) and RFS (Figure 3B; $P=.010$). Patients with ER β -positive also had poor prognosis in terms of RFS (Figure 3D; $P=.031$); an identical tendency was observed for OS (Figure 3C; $P=.079$). Furthermore, patients with high expression of aromatase and ER β -positive had a poorer prognosis than patients with low expression of aromatase and ER β -negative in terms of both OS (Figure 3E; $P=.004$) and RFS (Figure 3F; $P=.002$).

Conversely, no significant difference was noted in the survival of patients with EGFR mutant lung adenocarcinoma according to aromatase and ER β expression (Table S2 and Figure S1).

Survival analysis according to sex in patients with EGFR wild-type lung adenocarcinoma

Next, we performed a survival analysis stratified by sex to clarify the prognostic impact of hormonal effect on sex in patients with EGFR wild-type lung adenocarcinoma. Figure 4 shows the RFS curves of males and females with EGFR wild-type lung adenocarcinoma according to aromatase and ER β expression, respectively. High aromatase expression was significantly associated with poor prognosis only in females (Figure 4B; $P=.007$), whereas ER β -positive had a tendency for poor prognosis only in males (Figure 4C; $P=.051$). Furthermore, patients with high expression of aromatase and ER β -positive had a poorer prognosis than patients with low expression of aromatase and ER β -negative, but only among females (Figure 4F; $P=.008$).

Discussion

Understanding the role of estrogen and EGFR pathways in lung adenocarcinoma is necessary to develop new preventative and treatment strategies. We report here for the first time that aromatase and ER β expression are indepen-

Prognostic significance of aromatase/ER β in lung adenocarcinoma

dent, unfavorable prognostic factors in *EGFR* wild-type lung adenocarcinoma. Furthermore, regarding *EGFR* wild-type lung adenocarcinoma, we showed that high aromatase expression was a significant predictor of poor survival only in females, whereas ER β expression was an important predictor of poor survival only in males. These observations indicate that these pathways are important to a different extent in males and females with lung adenocarcinoma.

In our study, PR was detected only in 2.7%. The rate of PR expression in lung tumors varies among reports, ranging from no expression to marginal (22%-35%) or even high expression (39%-63%) [40]. This difference may be related to the antibody used in each study. The antibody we used is a representative PR antibody widely used for breast cancer research and to guide clinicians' choice of therapy. However, its use remains limited for lung tumors, and the most appropriate antibody for PR staining in lung tumors is yet to be identified.

Recent studies linking ER expression status with *EGFR* mutation have suggested that considering these signaling pathways together may provide important insight into lung cancer biology [31, 41-42]. Thus, we analyzed the association of aromatase/ER β expression with *EGFR* mutation status. Interestingly, our subgroup analysis showed a significant difference in OS and RFS according to aromatase expression, and a significant difference in RFS according to ER β expression, only in *EGFR* wild-type lung adenocarcinoma.

Mah et al. reported that low aromatase expression was found to be associated with favorable survival in female NSCLC patients in the United States [13]. However, in reports based on Asian populations, aromatase expression had no association with prognosis, although aromatase was expressed in more than 60% of lung cancer patients [14, 27]. The result of Mah's report [13] is consistent with that of ours, although those of later reports are not. However, those previous studies grouped adenocarcinoma and other histological types of NSCLC together. Furthermore, *EGFR* mutation status was not analyzed in those studies. The precise mechanism underlying the worse survival regarding the association of aromatase expression with *EGFR* mutation status in our study is unknown. However, the frequency of *EGFR* mutations in

NSCLC varies among races: from 27 to 60% in Asians and from 8 to 16% in Europeans, Africans, and Caucasian Americans [43-44]. Based on these observations and our findings, we speculate that the prognostic discrepancy in relation to the aromatase expression level among previous reports might be attributable to the difference in *EGFR* mutation status in each study.

To further examine aromatase and ER β as a predictor of survival, and to assess the importance of sex, we analyzed the association between aromatase/ER β expression and sex in *EGFR* wild-type patients according to survival. As expected, our result showed that high aromatase expression was a significant predictor of poor survival only in females, and we found no predictive value for aromatase expression levels in males. By contrast, our result showed that ER β -positive was a significant predictor of poor survival only in males, and we found no predictive value for ER β expression levels in females.

The differences in these sex-related results seem to depend on the difference in the status of, and sensitivity to, reproductive hormones according to sex. In postmenopausal females, circulating estrogen levels are decreased due to the decline in estrogen production by the ovaries [45]. Under these conditions, local estrogen production through aromatase might be an important determinant of estrogen levels. In fact, Niikawa et al. demonstrated that the intratumoral estradiol concentration was significantly higher in NSCLC than in nonneoplastic lung tissue and was positively correlated with intratumoral aromatase expression [46]. In our study, we did not distinguish females according to menopause status because only one of the females with *EGFR* wild-type lung adenocarcinoma was premenopausal. In other words, our result indicated that aromatase expression level is prognostic factor in postmenopausal females with *EGFR* wild-type lung adenocarcinoma. Therefore, intratumoral aromatase expression is associated with tumor progression via estrogen signaling pathway in postmenopausal females, particularly in *EGFR* wild-type lung adenocarcinoma.

In contrast to females, circulating estrogen levels in males are almost the same as those in postmenopausal females, and this condition

Prognostic significance of aromatase/ER β in lung adenocarcinoma

remains relatively constant with age [47]. Martin et al. demonstrated that ER-positive breast cancer cells are hypersensitive to low doses of estrogen with long-term estrogen deprivation [48]. Furthermore, in males, a higher level of androgen, which is a substrate of estrogen synthesis, is present than in females [47]. Based on these observations, at low expression levels, aromatase may produce an amount of estrogen sufficient for proliferation of ER-positive cells. In the present study, 92.1% of lung adenocarcinoma expressed aromatase at lower levels in males. Therefore, these findings support our hypothesis that lung adenocarcinoma in males supplies sufficient levels of estrogen to activate ER for tumor cell maintenance, and that the level of tumor proliferation activity-mediated via estrogen signaling pathway is more dependent on ER β than aromatase expression in males.

The role of AIs in lung adenocarcinoma is unclear. However, many studies have reported that AIs demonstrated significant anti-tumor effects in NSCLC expressing aromatase both in vitro and in vivo [12, 16, 33, 46, 49]. These observations and our findings revealed that *EGFR* wild-type lung adenocarcinoma patients with high aromatase expression are a suitable subset for AI treatment, particularly in postmenopausal females. Currently, a phase I clinical trial of the irreversible steroidal AI exemestane in combination with chemotherapy for late-stage lung cancer in postmenopausal females is underway (NCT01664754). We are awaiting the results of this phase I study, which may reveal that AI treatment is effective for lung cancer in postmenopausal females.

Stabile et al. reported that increased *EGFR* signaling might be caused by depletion of estrogen signals induced by endocrine therapy, and targeting both pathways could be beneficial for therapy [34]. A phase II trial of erlotinib (*EGFR*-TKI) or erlotinib + fulvestrant in previously treated male and female advanced NSCLC has been completed [Garon EB, Siegfried JM, Dubinett SM, Elashoff RM, Park DJ, Parikh RJ, Patel R, Hu EH, Reckamp KL, Adams B, Martinez D, Wang HJ, Kabbinnavar F, Dacic S, Brennan M, Laux I, Márquez-Garban DC, Stabile LP, Slamon DJ, Pietras RJ. Results of TORI-L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NS-

CLC). Presented at the 104th Annual Meeting of the American Association for Cancer Research; Washington DC, PA, April 6-10, 2013. p. Abstract 4664; Unpublished results]. Interestingly, the clinical benefit rate was significantly higher among patients treated with the combination compared with erlotinib alone among patients with *EGFR* wild-type tumors, although the survival and response rates were similar between the two treatment arms in unselected patients. The latter finding supports our suggestion that estrogen signaling pathway plays an important role in the development of *EGFR* wild-type lung adenocarcinoma. Thus, endocrine therapy could also be beneficial for *EGFR* wild-type lung adenocarcinoma as a combination therapy with *EGFR*-TKI.

The limitations of present study include selection of antibodies, the retrospective design, and relatively small number of patients, all of whom were Japanese. Thus, large, population-based prospective studies with ethnically diverse populations are warranted to elucidate the role of growth factor pathways, including *EGFR* and/or estrogen signaling pathways, in lung adenocarcinoma.

In conclusion, we demonstrated that aromatase and ER β expressions are independent negative prognostic factors in *EGFR* wild-type lung adenocarcinoma and that high aromatase expression is a significant predictor of poor survival only in females, whereas ER β -positive is an important predictor of poor survival only in males. We suggest that *EGFR* wild-type lung adenocarcinoma is a hormone-related carcinoma.

Acknowledgements

We thank Toshiaki Hikino (Division of Diagnostic Pathology, Graduate School of Medicine, Gunma University) for skillful technical assistance. The first author was supported by Grant-in-Aid for Young Scientists (B) (24791454) from Japan Society for the Promotion of Science (JSPS).

Disclosure of conflict of interest

None.

Address correspondence to: Kimihiro Shimizu, Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-85-11, Japan. Tel: 81-27-220-8245; Fax: 81-27-220-8255; E-mail: kmshimizu@gmail.com

Prognostic significance of aromatase/ER β in lung adenocarcinoma

References

- [1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 2009; 59: 225-249.
- [2] Subramanian J, Govindan R. Lung cancer in never smokers: a review. *J Clin Oncol* 2007; 25: 561-570.
- [3] Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artifact? A review of the epidemiology of lung adenocarcinoma. *Int J Epidemiol* 1997; 26: 14-23.
- [4] Lam B, Lam WK, Lam CL, Ooi GC, Ho JCM, Wong MP, Tsang KW. Adenocarcinoma of the lung in Chinese patients: a revisit and some perspectives from the literature. *Postgrad Med J* 2001; 77: 708-712.
- [5] Kakegawa S, Shimizu K, Sugano M, Miyamae Y, Kaira K, Araki T, Nakano T, Kamiyoshihara M, Kawashima O, Takeyoshi I. Clinicopathological features of lung adenocarcinoma with KRAS mutations. *Cancer* 2011; 117: 4257-4266.
- [6] Verma MK, Miki Y, Sasano H. Aromatase in human lung carcinoma. *Steroids* 2011; 76: 759-764.
- [7] Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. *Cancer Res* 2002; 62: 2141-2150.
- [8] Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. *Cancer Res* 2005; 65: 1598-1605.
- [9] Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson JÅ, Hayashi S. Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. *Biochem Biophys Res Commun* 2001; 285: 340-347.
- [10] Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors α and β in human lung tissues and cell lines. *Lung Cancer* 2002; 37: 153-159.
- [11] Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorance S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. *Endocr Rev* 1994; 15: 342-344.
- [12] Weinberg OK, Márquez-Garban DC, Fishbein MC, Goodglick L, Hermes J. Garban, Dubinett SM, Pietras RJ. Aromatase inhibitors in human lung cancer therapy. *Cancer Res* 2005; 65: 11287-11291.
- [13] Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, Fishbein MC, Chia D, Pietras RJ, Goodglick L. Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. *Cancer Res* 2007; 67: 10484-10490.
- [14] Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, Kudo N, Koguchi M, Niikawa H, Suzuki S, Evans DB, Sugawara S, Suzuki T, Sasano H. Highly concordant coexpression of aromatase and estrogen receptor β in non-small cell lung cancer. *Hum Patol* 2009; 41: 190-198.
- [15] Gustafsson JÅ. Estrogen receptor beta - a new dimension in estrogen mechanism of action. *J Endocrinol* 1999; 163: 379-383.
- [16] Miki Y, Suzuki T, Abe K, Suzuki S, Niikawa H, Iida S, Hata S, Akahira J, Mori K, Evans DB, Kondo T, Yamada-Okabe H, Sasano H. Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. *Cancer Res* 2010; 70: 6659-6669.
- [17] Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ER β expression as a common step in estrogen-dependent tumor progression. *Endocr Relat Cancer* 2004; 11: 537-551.
- [18] Skliris GP, Leygue E, Watson PH, Murphy LC. Estrogen receptor α negative breast cancer patients: estrogen receptor β as a therapeutic target. *J Steroid Biochem Mol Biol* 2008; 109: 1-10.
- [19] Grubberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg Å, Fernö M. Estrogen receptor β expression is associated with tamoxifen response in ER α -negative breast carcinoma. *Clin Cancer Res* 2007; 13: 1987-1994.
- [20] Cheng G, Weihua Z, Warner M, Gustafsson JÅ. Estrogen receptors ER α and ER β in proliferation in the rodent mammary gland. *Proc Natl Acad Sci U S A* 2004; 101: 3739-3746.
- [21] Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the estrogen receptor β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. *Am J Pathol* 2001; 159: 79-92.
- [22] Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, Nakachi K, Gustafsson JÅ, Hayashi S. Estrogen receptor β is expressed in human stomach adenocarcinoma. *J Cancer Res Clin Oncol* 2002; 128: 319-324.
- [23] Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor β in 301 surgically

Prognostic significance of aromatase/ER β in lung adenocarcinoma

- treated non-small cell lung cancers. *J Thoracic Cardiovasc Surg* 2005; 130: 979-986.
- [24] Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, Brooks S. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. *Clin Cancer Res* 2005; 11: 7280-7287.
- [25] Skov BG, Fisher BM, Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. *Lung Cancer* 2008; 59: 88-94.
- [26] Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor β -1 and progesterone receptor expression identifies lung cancer patients with poor outcome. *Clin Cancer Res* 2011; 17: 154-164.
- [27] Verma MK, Miki Y, Abe K, Nagasaki S, Niikawa H, Suzuki S, Kondo T, Sasano H. Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome. *Life Sci* 2012; 91: 800-808.
- [28] Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med* 2011; 62: 233-247.
- [29] Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. *Nat Rev Cancer* 2009; 9: 631-643.
- [30] Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H. Suppression of estrogen actions in human lung cancer. *Mol Cell Endocrinol* 2011; 340: 168-174.
- [31] Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, Onitsuka T, Yasumoto K. Association between estrogen receptor- β expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. *J Clin Oncol* 2009; 27: 411-417.
- [32] Pietras RJ, Márquez DC. Membrane-associated estrogen receptor signaling pathways in human cancers. *Clin Cancer Res* 2007; 13: 4672-4676.
- [33] Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, Kalofonos H. Antiproliferative effect of exemestane in lung cancer cells. *Mol Cancer* 2009; 8: 109.
- [34] Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. *Cancer Res* 2005; 65: 1459-1470.
- [35] Shen H, Yuan Y, Sun J, Gao W, Shu YQ. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. *Biomed Pharmacother* 2010; 64: 88-92.
- [36] Leslie Sobin MG CW (ed). *TNM Classification of Malignant Tumors*, 7th Ed. Geneva, UICC International Union Against Cancer; 2009. pp. 136-146.
- [37] Araki T, Shimizu K, Nakamura T, Baba M, Kawai Y, Nakamura K, Mitani Y, Obayashi K, Aomori T, Fujita Y, Miyamae Y, Kakegawa S, Kaira K, Lezhava A, Hayashizaki Y, Takeyoshi I, Yamamoto K. Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma. *Oncol Rep* 2011; 26: 1213-1219.
- [38] Miyamae Y, Shimizu K, Mitani Y, Araki T, Kawai Y, Baba M, Kakegawa S, Sugano M, Kaira K, Lezhava A, Hayashizaki Y, Yamamoto K, Takeyoshi I. Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. *J Mol Diagn* 2010; 12: 257-264.
- [39] Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. *Mod Pathol* 1998; 11: 155-168.
- [40] Kishi S, Yokohira M, Yamakawa K, Saoo K, Imaida K. Significance of the progesterone receptor and epidermal growth factor receptor, but not the estrogen receptor, in chemically induced lung carcinogenesis in female A/J mice. *Oncol Letters* 2014; 8: 2379-2386.
- [41] Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. *Clin Cancer Res* 2009; 15: 5359-5368.
- [42] Toh CK, Ahmad B, Soong R, Chuah KL, Tan SH, Hee SW, Leong SS, Tan EH, Lim WT. Correlation between epidermal growth factor receptor mutation and expression of female hormone receptors in East-Asian lung adenocarcinomas. *J Thorac Oncol* 2010; 5: 17-22.
- [43] Tam IYS, Chung LP, Suen WS, Wang E, Wong MCM, Ho KK, Lam WK, Chiu SW, Girard L, Minna JD, Gazdar AF, Wong MP. Distinct epidermal growth factor receptor and KRAS mutation patterns in nonsmall cell lung cancer patients with different tobacco exposure and clinicopathologic features. *Clin Cancer Res* 2006; 12: 1647-1653.
- [44] Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer* 2001; 92: 1525-1530.

Prognostic significance of aromatase/ER β in lung adenocarcinoma

- [45] Folkard EJ, Martin LA, Kendall A, Dowsett M. The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. *J Steroid Biochem Mol Biol* 2006; 102: 250-255.
- [46] Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S, Kondo T, Sasano H. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. *Clin Cancer Res* 2008; 14: 4417-4426.
- [47] Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. *Aging Male* 2002; 5: 98-102.
- [48] Martin LA, Farmer I, Johnston SRD, Ali S, Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. *Endocrine-Related Cancer* 2005; 12: S75-S84.
- [49] Márquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. *Ann NY Acad Sci* 2009; 1155: 194-205.

Prognostic significance of aromatase/ER β in lung adenocarcinoma

Table S1. Association between clinicopathological factors and immunoreactivity for aromatase in 150 lung adenocarcinomas

	Aromatase				P value	ER β				P value
	High expression		Low expression			Positive		Negative		
	N = 72	% (range)	N = 78	% (range)		N = 119	% (range)	N = 31	% (range)	
Age (years: median 69)	68	(40–83)	65	(36–84)	0.077	67	(40–83)	63	(36–84)	0.066
Sex										
Male	33	22.0	30	20.0		48	32.0	15	10.0	
Female	39	26.0	48	32.0	0.361	71	47.3	16	10.7	0.272
Smoking status										
Ever-smoker	35	23.3	33	22.0		54	36.0	14	9.3	
Non-smoker	37	24.7	45	30.0	0.438	65	43.4	17	11.3	0.573
Tumor diameter (mm)	25	(7–53)	23	(6–70)	0.377	25	(7–70)	20	(6–60)	0.050
Pathologic stage										
IA	38	25.3	47	31.4		62	41.3	23	15.4	
IB	14	9.3	12	8.0		23	15.4	3	2.0	
IIA	2	1.3	3	2.0		5	3.3	0	0.0	
IIB	4	2.7	2	1.3		4	2.7	2	1.3	
IIIA	12	8.0	10	6.7		20	13.3	2	1.3	
IIIB	2	1.3	4	2.7	0.763	5	3.3	1	0.7	0.207
Pleural invasion										
Absent	43	28.7	59	39.3		79	52.6	23	15.4	
Present	29	19.3	19	12.7	0.037	40	26.7	8	5.3	0.589
Lymphatic invasion										
Absent	48	32.0	53	35.3		79	52.6	22	14.7	
Present	24	16.0	25	16.7	0.867	40	26.7	9	6.0	0.399
Vascular invasion										
Absent	47	31.3	57	38.0		80	53.3	24	16.0	
Present	25	16.7	21	14.0	0.301	39	26.0	7	4.7	0.191
EGFR mutation										
Mutant	33	23.6	29	20.7		53	37.9	9	6.4	
Wild type	35	25.0	43	30.7	0.326	59	42.1	19	13.6	0.108
KRAS mutation										
Mutant	10	7.1	13	9.3		19	13.6	4	2.9	
Wild type	58	41.4	59	42.2	0.593	93	66.4	24	17.1	0.493
Aromatase										
High expression						60	40.0	12	8.0	
Low expression						59	39.3	19	12.7	0.168
ER α										
Positive	1	0.7	1	0.7		2	1.3	0	0.0	
Negative	71	47.3	77	51.3	0.731	117	78.0	31	20.7	0.628
ER β										
Positive	60	40.0	59	39.3						
Negative	12	8.0	19	12.7	0.168					
PR										
Positive	2	1.3	2	1.3		4	2.7	0	0.0	
Negative	70	46.7	76	50.7	0.659	115	76.7	31	20.6	0.392
HER2										
Positive	4	2.7	3	2.0		7	4.7	0	0.0	
Negative	68	45.3	75	50.0	0.455	112	74.7	31	20.6	0.190
Ki-67 LI (%)	18.9	(1.0–63.1)	17.3	(0.2–93.6)	0.582	18.2	(1.0–66.4)	17.5	(0.2–93.6)	0.865

EGFR, epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LI, labeling index.

Prognostic significance of aromatase/ER β in lung adenocarcinoma

Table S2. Univariate analysis of prognostic factors using the log-rank test in *EGFR* mutant cases

Variable	No. of patients (%)	5-year OS (%)	Univariate <i>P</i> value	5-year RFS (%)	Univariate <i>P</i> value
All cases	62 (100.0)	83.9		69.3	
Age (years: median 69)					
<69	34 (54.8)	85.3		67.5	
\geq 69	28 (45.2)	82.1	0.487	71.4	0.854
Sex					
Male	19 (30.6)	89.5		73.7	
Female	43 (69.4)	81.4	0.393	67.4	0.678
Smoking status					
Ever-smoker	19 (30.6)	84.2		63.2	
Non-smoker	43 (69.4)	83.7	0.867	72.1	0.500
Pathologic stage					
I, II	33 (53.2)	92.2		82.4	
III	29 (46.8)	36.4	<0.001	9.1	<0.001
Pleural invasion					
Absent	48 (77.4)	87.5		74.9	
Present	14 (22.6)	71.4	0.198	50.0	0.039
Lymphatic invasion					
Absent	46 (74.2)	91.3		82.6	
Present	16 (25.8)	62.5	0.016	31.3	<0.001
Vascular invasion					
Absent	47 (75.8)	89.4		80.9	
Present	15 (24.2)	66.7	0.078	33.3	0.001
<i>KRAS</i> mutation					
Mutant	0 (0.0)	—		—	
Wild type	62 (100.0)	83.9	—	69.3	—
Aromatase					
High expression	33 (53.2)	81.8		69.7	
Low expression	29 (46.8)	86.2	0.861	69.0	0.915
ER α					
Positive	0 (0.0)	—		—	
Negative	62 (100.0)	83.9	—	69.3	—
ER β					
Positive	53 (85.5)	84.9		67.9	
Negative	9 (14.5)	77.8	0.575	77.8	0.677
PR					
Positive	1 (1.6)	100.0		100.0	
Negative	61 (98.4)	83.6	0.649	68.8	0.542
HER2					
Positive	3 (4.8)	66.7		33.3	
Negative	59 (95.2)	84.7	0.501	71.1	0.034
Ki-67 LI (%: median 11.5)					
Low score	33 (53.2)	93.9		90.9	
High score	29 (46.8)	72.4	0.011	44.8	<0.001

OS, overall survival; RFS, recurrence-free survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LI, labeling index.

Prognostic significance of aromatase/ER β in lung adenocarcinoma




Figure S1. Kaplan-Meier survival curves of 62 lung adenocarcinoma patients with EGFR mutations according to the immunoreactivity results for aromatase and ER β . A. Overall (OS) stratified by high versus low expression of aromatase. B. Recurrence-free survival (RFS) stratified by high versus low expression of aromatase. C. OS stratified by positive versus negative expression of ER β . D. RFS stratified by positive versus negative expression of ER β .